Nemolizumab
- Generic Name
- Nemolizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1476039-58-3
- Unique Ingredient Identifier
- GN465U8B72
- Background
Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
- Associated Conditions
- -
- Associated Therapies
- -
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1700
- Registration Number
- NCT03989206
- Locations
- 🇺🇸
Galderma Investigational Site 8206, Norman, Oklahoma, United States
🇺🇸Galderma Investigational Site 8737, Miami, Florida, United States
🇺🇸Galderma Investigational Site 8706, Miami, Florida, United States
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 787
- Registration Number
- NCT03989349
- Locations
- 🇺🇸
Galderma Investigational Site 8721, Pittsburgh, Pennsylvania, United States
🇺🇸Galderma Investigational Site 8807, Houston, Texas, United States
🇺🇸Galderma Investigational Site 8719, Miami, Florida, United States
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 941
- Registration Number
- NCT03985943
- Locations
- 🇨🇦
Galderma Investigational Site 8336, Toronto, Ontario, Canada
🇺🇸Galderma Investigational Site 8882, Bangor, Maine, United States
🇵🇱Galderma Investigational Site 6243, Gdańsk, Poland
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 226
- Registration Number
- NCT03100344
- Locations
- 🇺🇸
Galderma Investigational site, Richmond, Virginia, United States
🇵🇱Galderma Investigational Site, Łódź, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.